{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=7", "query": { "intervention": "Placebo (0.9% Sodium chloride) infusion", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 416, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:35:26.331Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01366820", "title": "Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Injuries" ], "interventions": [ { "name": "NNZ-2566", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neuren Pharmaceuticals Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 261, "start_date": "2013-02", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 6, "location_summary": "Colton, California • Sacramento, California • Honolulu, Hawaii + 2 more", "locations": [ { "city": "Colton", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366820" }, { "nct_id": "NCT01720524", "title": "A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Hypertension, Familial Persistent, of the Newborn" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "iv sildenafil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "4 Days", "sex": "ALL", "summary": "0 Days to 4 Days" }, "enrollment_count": 59, "start_date": "2013-08-05", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01720524" }, { "nct_id": "NCT04924660", "title": "Novel Experimental COVID-19 Therapies Affecting Host Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19", "SARS-CoV-2 Infection", "Coronavirus Infection" ], "interventions": [ { "name": "TXA127", "type": "DRUG" }, { "name": "TRV027", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sean Collins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1060, "start_date": "2021-07-15", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04924660" }, { "nct_id": "NCT00808665", "title": "Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Spinal Fusion Acquired", "Spinal Stenosis", "Lesions of Lumbosacral Intervertebral Disc", "Spinal Diseases" ], "interventions": [ { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "0.9% Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 68, "start_date": "2009-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808665" }, { "nct_id": "NCT01405508", "title": "Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam tablets", "type": "DRUG" }, { "name": "Brivaracetam bolus", "type": "DRUG" }, { "name": "Brivaracetam infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2011-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405508" }, { "nct_id": "NCT05324358", "title": "Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "Ketorolac Tromethamine", "type": "DRUG" }, { "name": "Morphine Sulfate", "type": "DRUG" }, { "name": "Intravenous Placebo for NTM-001", "type": "OTHER" }, { "name": "IV Placebo for Morphine", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neumentum, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 341, "start_date": "2022-12-14", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 10, "location_summary": "Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05324358" }, { "nct_id": "NCT02770807", "title": "Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nervous System Disease", "Genetic Syndrome" ], "interventions": [ { "name": "EryDex Low dose DSP", "type": "DRUG" }, { "name": "EryDex High dose DSP", "type": "DRUG" }, { "name": "Pooled Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quince Therapeutics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 176, "start_date": "2017-03-02", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02770807" }, { "nct_id": "NCT05645107", "title": "A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypogammaglobulinemia", "Bacterial Infections", "B-cell Chronic Lymphocytic Leukemia", "Multiple Myleoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Xembify", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2022-12-26", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 9, "location_summary": "Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645107" }, { "nct_id": "NCT05386823", "title": "Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "HF1K16", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HighField Biopharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2021-03-20", "completion_date": "2021-08-04", "has_results": true, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 1, "location_summary": "Secaucus, New Jersey", "locations": [ { "city": "Secaucus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05386823" }, { "nct_id": "NCT03049930", "title": "Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Burns" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Sodium chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 46, "start_date": "2018-02-27", "completion_date": "2020-08", "has_results": false, "last_update_posted_date": "2019-03-14", "last_synced_at": "2026-10-14T00:35:26.331Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049930" } ] }